Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 046513107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Panacea Innovation Ltd
13D/A
Amendment 3
|
16.1% |
5/11/2026
Event 5/7/2026
|
|
| Panacea Innovation Limited | 16.1% | ||
| Panacea Venture Healthcare Fund II, L.P. | 12.4% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 12.4% | ||
| Panacea Opportunity Fund I, L.P. | 3.8% | ||
| Panacea Opportunity Fund I GP Company, Ltd. | 3.8% | ||
| James Huang | 16.1% | ||
|
Panacea Innovation Ltd
13D/A
Amendment 2
|
20.0% |
1/14/2026
Event 1/12/2026
|
|
| Panacea Innovation Limited | 20.0% | ||
| Panacea Venture Healthcare Fund II, L.P. | 18.2% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 18.2% | ||
| Panacea Opportunity Fund I, L.P. | 4.1% | ||
| Panacea Opportunity Fund I GP Company, Ltd. | 4.1% | ||
| James Huang | 20.0% | ||
|
Panacea Innovation Ltd
13D/A
Amendment 1
|
20.0% |
8/19/2025
Event 8/15/2025
|
|
| Panacea Innovation Limited | 20.0% | ||
| Panacea Venture Healthcare Fund II, L.P. | 20.0% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 20.0% | ||
| Panacea Opportunity Fund I, L.P. | 4.2% | ||
| Panacea Opportunity Fund I GP Company, Ltd. | 4.2% | ||
| James Huang | 20.0% | ||
|
Panacea Innovation Ltd
13D
|
20.0% |
5/21/2025
Event 5/16/2025
|
|
| Panacea Innovation Limited | 20.0% | ||
| Panacea Venture Healthcare Fund II, L.P. | 19.6% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 19.6% | ||
| Panacea Opportunity Fund I, L.P. | 4.3% | ||
| Panacea Opportunity Fund I GP Company, Ltd. | 4.3% | ||
| James Huang | 20.0% | ||
|
Adiumentum Capital Fund I LP
13D/A
Amendment 2
|
20.0% |
5/16/2025
Event 5/14/2025
|
|
| Adiumentum Capital Fund I LP | 20.0% | ||
| Adiumentum Capital Fund I GP LLC | 20.0% | ||
| Gregory A. Ciongoli | 20.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 1 | 28.0 | $321.00 |
| 2026 Q1 | 1 | 28.0 | $132.00 |
| 2025 Q3 | 1 | 15.0 | $215.00 |
| 2024 Q4 | 2 | 63.0 | $839.00 |
| 2024 Q3 | 1 | 35.0 | $285.00 |
| 2024 Q2 | 5 | 182 k | $1.51 M |
| 2024 Q1 | 88 | 87.3 M | $60.7 M |
| 2023 Q4 | 97 | 69.3 M | $35.5 M |
| 2023 Q3 | 119 | 88.2 M | $131 M |
| 2023 Q2 | 127 | 90.5 M | $146 M |
| 2023 Q1 | 131 | 103 M | $298 M |
| 2022 Q4 | 146 | 105 M | $345 M |
| 2022 Q3 | 161 | 100 M | $378 M |
| 2022 Q2 | 139 | 99.8 M | $778 M |
| 2022 Q1 | 153 | 97.9 M | $910 M |
| 2021 Q4 | 145 | 95.6 M | $1.51 B |
| 2021 Q3 | 144 | 89.7 M | $1.61 B |
| 2021 Q2 | 149 | 86.0 M | $1.34 B |
| 2021 Q1 | 154 | 86.7 M | $1.24 B |
| 2020 Q4 | 162 | 87.6 M | $1.72 B |
| 2020 Q3 | 149 | 83.8 M | $1.09 B |
| 2020 Q2 | 131 | 77.8 M | $1.13 B |
| 2020 Q1 | 121 | 63.0 M | $536 M |
| 2019 Q4 | 127 | 62.0 M | $1.02 B |
| 2019 Q3 | 124 | 59.0 M | $833 M |
| 2019 Q2 | 134 | 50.5 M | $1.01 B |
| 2019 Q1 | 131 | 48.9 M | $1.94 B |
| 2018 Q4 | 128 | 48.8 M | $1.69 B |
| 2018 Q3 | 127 | 47.1 M | $1.95 B |
| 2018 Q2 | 143 | 47.0 M | $1.73 B |
| 2018 Q1 | 131 | 43.9 M | $1.71 B |
| 2017 Q4 | 91 | 29.9 M | $542 M |
| 2017 Q3 | 86 | 26.6 M | $441 M |
| 2017 Q2 | 93 | 25.7 M | $360 M |
| 2017 Q1 | 91 | 24.1 M | $496 M |
| 2016 Q4 | 90 | 23.3 M | $331 M |
| 2016 Q3 | 78 | 22.4 M | $479 M |
| 2016 Q2 | 76 | 21.8 M | $493 M |
| 2016 Q1 | 74 | 19.8 M | $377 M |
| 2015 Q4 | 95 | 19.3 M | $510 M |
| 2015 Q3 | 95 | 20.1 M | $644 M |
| 2015 Q2 | 77 | 13.2 M | $696 M |
| 2015 Q1 | 54 | 11.2 M | $462 M |
| 2014 Q4 | 42 | 6.76 M | $173 M |